$IBIO

iBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy Completed dosing in the single ascending dose p

iBio, Inc. (IBIO) will report Q1'27 earnings on November 17, with revenue estimated at $25,000 and EPS at -$0.07. The exact time of the announcement is not specified.

iBio, Inc. (IBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, iBio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At th

iBio, Inc. (IBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, vers

iBio Inc. (IBIO) reported preclinical data showing its obesity drug candidate, IBIO-610, combined with semaglutide, preserved lean mass and increased fat loss in obese non-human primates. The study found a 97% reduction in Activin E levels and a 33.2-day half-life for the antibody. The company plans to start human trials in 2027. According to the CEO, the data suggests potential for improved weight loss quality. iBio is a clinical-stage biotech firm focusing on obesity and related diseases.

Analysts cut iBio Inc.'s 12-month price target from $5.69 to $5.53, with forecasts ranging from $4.2 to $7. The new target implies 447% upside from the Oct. 7 closing price. All 8 analysts maintain a 'Buy' rating.

H.C. Wainwright initiated coverage on iBio Inc. (NASDAQ:IBIO) with a buy rating and a $7.00 price target, citing potential in its obesity and diabetes treatments. The stock has declined 52% over six months. The firm highlighted the company's cash position of $88.0 million as of June 30, 2026, with runway extending into 2028, despite high cash burn.

iBio Inc. (IBIO) reported a wider net loss of $33.04 million for FY 2026, up from $18.38 million in 2025, due to increased R&D expenses. Revenues fell to $0.10 million from $0.40 million. The company has $88 million in cash. IBIO-600 Phase 1 trial for obesity showed positive data, and IBIO-610 showed promising preclinical results. IBIO stock closed at $1.36, up 2.20% after hours.

iBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic an

iBio, Inc. (IBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer SAN DIEGO, August 4, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesi